X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs VENUS REMEDIES - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH VENUS REMEDIES PANACEA BIOTECH/
VENUS REMEDIES
 
P/E (TTM) x -19.2 -8.3 - View Chart
P/BV x 2.7 0.1 2,082.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PANACEA BIOTECH   VENUS REMEDIES
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
VENUS REMEDIES
Mar-17
PANACEA BIOTECH/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs149143 104.1%   
Low Rs8265 126.6%   
Sales per share (Unadj.) Rs84.1324.2 26.0%  
Earnings per share (Unadj.) Rs-18.36.4 -285.6%  
Cash flow per share (Unadj.) Rs-6.740.6 -16.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.7366.0 22.9%  
Shares outstanding (eoy) m61.2512.34 496.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.40.3 428.3%   
Avg P/E ratio x-6.316.2 -38.9%  
P/CF ratio (eoy) x-17.22.6 -673.3%  
Price / Book Value ratio x1.40.3 486.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,0741,282 551.8%   
No. of employees `0002.80.9 304.5%   
Total wages/salary Rs m1,449251 577.4%   
Avg. sales/employee Rs Th1,874.14,430.1 42.3%   
Avg. wages/employee Rs Th527.0278.0 189.6%   
Avg. net profit/employee Rs Th-407.787.6 -465.5%   
INCOME DATA
Net Sales Rs m5,1544,000 128.8%  
Other income Rs m10023 439.6%   
Total revenues Rs m5,2544,023 130.6%   
Gross profit Rs m-766785 -97.7%  
Depreciation Rs m711422 168.6%   
Interest Rs m1,503344 437.3%   
Profit before tax Rs m-2,88142 -6,842.0%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17-37 -45.4%   
Profit after tax Rs m-1,12179 -1,417.6%  
Gross profit margin %-14.919.6 -75.8%  
Effective tax rate %-0.6-87.9 0.7%   
Net profit margin %-21.82.0 -1,100.3%  
BALANCE SHEET DATA
Current assets Rs m3,8102,606 146.2%   
Current liabilities Rs m8,3651,980 422.4%   
Net working cap to sales %-88.415.6 -564.9%  
Current ratio x0.51.3 34.6%  
Inventory Days Days156128 121.4%  
Debtors Days Days6743 155.8%  
Net fixed assets Rs m14,4805,353 270.5%   
Share capital Rs m61123 49.7%   
"Free" reserves Rs m9034,393 20.6%   
Net worth Rs m5,1274,516 113.5%   
Long term debt Rs m5,8321,618 360.4%   
Total assets Rs m19,4338,291 234.4%  
Interest coverage x-0.91.1 -81.6%   
Debt to equity ratio x1.10.4 317.4%  
Sales to assets ratio x0.30.5 55.0%   
Return on assets %2.05.1 38.5%  
Return on equity %-21.91.8 -1,248.6%  
Return on capital %3.66.3 57.8%  
Exports to sales %24.50-   
Imports to sales %10.218.4 55.3%   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525736 71.3%   
Fx inflow Rs m1,5390-   
Fx outflow Rs m942736 127.9%   
Net fx Rs m597-736 -81.1%   
CASH FLOW
From Operations Rs m599997 60.1%  
From Investments Rs m-438-461 94.9%  
From Financial Activity Rs m-303-571 53.0%  
Net Cashflow Rs m-141-35 402.6%  

Share Holding

Indian Promoters % 74.5 32.9 226.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 0.2 333.3%  
FIIs % 1.3 0.6 224.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 66.4 35.5%  
Shareholders   10,259 20,121 51.0%  
Pledged promoter(s) holding % 35.1 36.4 96.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ALEMBIC PHARMA  STRIDES SHASUN LTD  FDC LTD.  ASTRAZENECA PHARMA  BIOCON LTD  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Depreciating Rupee; IPO Buzz and Top Cues in Focus Today(Pre-Open)

Indian share markets ended lower yesterday with banking stocks and metal stocks leading the losses. At the closing bell, the BSE Sensex ended down by 188 points (0.5%).

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Aug 16, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - FDC LTD. COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS